Key facts
- It has raised $2.4M; the latest was Early Stage VC ($2.4M) in Mar 2026.
- Notable investors include Tech Incubator Program for Startup, Hana Ventures, Korea Investment Accelerator, IBK Venture Investment, Bluepoint — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Protier Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Protier Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Protier Biotech
Operator of a biomedical firm intended to develop a molecular glue that degrades as a payload of antibody-drug conjugates. The company's small-molecule drugs connect to linkers and are effective at low drug concentrations, enabling healthcare professionals to remove damaged or unnecessary proteins without damaging other cells to maintain homeostasis.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2022
- Employees
- 5
- Website
- protierbiotech.com/
- Ownership
- Privately Held (backing)
Protier Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Protier Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Protier Biotech in its N-PORT filings yet. We sweep new filings monthly.